ISEC Healthcare (40T) Q2 2025 earnings summary

Executive summary

• Revenue rose 7% year-over-year to $37.82 million for the six months ended 30 June 2025, driven by increased business activities and new centre openings, especially in specialised health services.

• Net profit increased 3% year-over-year to $6.87 million, with gross profit margin stable at 44.8%.

• Administrative expenses rose due to expansion and higher staff costs, while other expenses declined as certain intangible assets were fully amortised.

Financial highlights

• Revenue: $37.82 million (+7% YoY); Gross profit: $16.96 million (+8% YoY); Net profit: $6.87 million (+3% YoY).

• Earnings per share (basic and diluted): 1.18 cents (up from 1.14 cents YoY).

• Cash and cash equivalents at period end: $14.89 million (down from $15.91 million at 31 Dec 2024).

• Final dividend of 0.70 cents per share paid for FY2024; no interim dividend declared for 1H2025.

Outlook and guidance

• Construction of new Kuala Lumpur facility is on schedule, with operations expected to commence by 2027.

• The group is exploring expansion opportunities in Vietnam and Myanmar, while strengthening its core markets.

• No interim dividend declared to preserve liquidity for strategic expansion.